<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551928</url>
  </required_header>
  <id_info>
    <org_study_id>RV-MM-PI-209</org_study_id>
    <nct_id>NCT00551928</nct_id>
  </id_info>
  <brief_title>Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients</brief_title>
  <acronym>MPRvsMEL200</acronym>
  <official_title>A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione EMN Italy Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione EMN Italy Onlus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of the combination of lenalidomide with low-dose melphalan versus&#xD;
      high-dose melphalan in newly diagnosed, symptomatic MM patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Over all survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Newly Diagnosed Patients</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral therapy with Lenalidomide Melphalan and Prednisone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose Melphalan therapy (200mg/sm)with autologous stem cell support, for 2 cycles every 4 months (only 1 cycle if the patient reached almost a VGPR after the 1st MEL200)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>High dose Melphalan 200mg/sm with autologous stem cell support</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is, in the investigator(s) opinion, willing and able to comply with the&#xD;
             protocol requirements.&#xD;
&#xD;
          -  Patient has given voluntary written informed consent before performance of any&#xD;
             study-related procedure not part of normal medical care, with the understanding that&#xD;
             consent may be withdrawn by the patient at any time without prejudice to their future&#xD;
             medical care.&#xD;
&#xD;
          -  Patient is 65 years old or younger at the time of signing the informed consent&#xD;
&#xD;
          -  Female patient is either post-menopausal or surgically sterilized or willing to use an&#xD;
             acceptable double method of birth control (i.e., a hormonal contraceptive,&#xD;
             intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence)&#xD;
             for the duration of the study.&#xD;
&#xD;
          -  Negative serum β-human chorionic gonadotropin ( β-HCG) pregnancy test both 24 hours&#xD;
             prior to beginning of therapy and then at 4 weeks intervals in women with regular&#xD;
             menstrual cycles or every 2 weeks in women with irregular menstrual cycles during&#xD;
             study treatment for subjects of childbearing potential&#xD;
&#xD;
          -  Male patient agrees to use an acceptable method for contraception (i.e., condom or&#xD;
             abstinence) during study drug therapy (including dose interruption) and for 4 weeks&#xD;
             after discontinuation of lenalidomide therapy.&#xD;
&#xD;
          -  Patient was diagnosed with symptomatic multiple myeloma based on standard criteria&#xD;
             (9), and has measurable disease, defined as follows: any quantifiable serum monoclonal&#xD;
             protein value (generally, but not necessarily, greater than 1 g/dL of IgG M-Protein&#xD;
             and greater than 0.5 g/dL of IgA M-Protein) and, where applicable, urine light-chain&#xD;
             excretion of &gt;200 mg/24 hours; measurable plasmacytoma &gt; 2 cm as determined by&#xD;
             clinical examination or applicable radiographs (i.e. MRI, CT-Scan); bone marrow plasma&#xD;
             cells&gt;10%.&#xD;
&#xD;
          -  Patient has a Karnofsky performance status ≥ 60%.&#xD;
&#xD;
          -  Patient has a life-expectancy &gt; 6 months&#xD;
&#xD;
          -  Patient has not active infectious hepatitis type B or C, and has HIV negative test&#xD;
&#xD;
          -  Patients must have an ejection fraction by ECHO or MUGA &gt; 50% performed within 60 days&#xD;
             prior to registration&#xD;
&#xD;
          -  Patients must have adequate pulmonary function studies &gt; 50% of predicted on&#xD;
             mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) &gt; 50% of predicted.&#xD;
             Patients unable to complete pulmonary function tests because of myeloma-related chest&#xD;
             pain, must have a high resolution CT scan of the chest and must also have acceptable&#xD;
             arterial blood gases defined as P02 greater than 70.&#xD;
&#xD;
          -  Patient has the following laboratory values within 14 days before Baseline (day 1 of&#xD;
             the Cycle 1):&#xD;
&#xD;
               -  Platelet count ≥ 75 x 109/L without transfusion support within 7 days before the&#xD;
                  test.&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without the use of growth factors.&#xD;
&#xD;
               -  Corrected serum calcium ≤ 14 mg/dL (3.5 mmol/L).&#xD;
&#xD;
               -  Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal (ULN).&#xD;
&#xD;
               -  Alanine transaminase (ALT): ≤ 2.5 x the ULN.&#xD;
&#xD;
               -  Total bilirubin: ≤ 1.5 x the ULN.&#xD;
&#xD;
               -  Calculated or measured creatinine clearance: ≥ 30 mL/minute&#xD;
&#xD;
          -  Patient has a baseline bone marrow sample available for cytogenetics, that will be&#xD;
             processed and eventually centralized within each country.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with anti-myeloma therapy (does not include radiotherapy,&#xD;
             bisphosphonates, or a single short course of steroid; &lt; to the equivalent of&#xD;
             dexamethasone 40 mg/day for 4 days).&#xD;
&#xD;
          -  Any serious medical condition, including the presence of laboratory abnormalities,&#xD;
             which places the subject at an unacceptable risk if he or she participates in this&#xD;
             study or confounds the experimental ability to interpret data from the study.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Prior history of malignancies, other than multiple myeloma, unless the subject has&#xD;
             been free of the disease for ≥ 3 years. Exceptions include the following: Basal cell&#xD;
             carcinoma of the skin, Squamous cell carcinoma of the skin, Carcinoma in situ of the&#xD;
             cervix, Carcinoma in situ of the breast, Incidental histologic finding of prostate&#xD;
             cancer (TNM stage of T1a or T1b)&#xD;
&#xD;
          -  Neuropathy of ≥ grade 2 severity.&#xD;
&#xD;
          -  Patients previously diagnosed as bearing deep venous thrombosis or arterial&#xD;
             thromboembolic event within the latest 12 months, or bearing a clear indication for&#xD;
             anti-platelet or anticoagulant therapy or bearing a high risk of bleeding&#xD;
             complications are ineligible for the sub-study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca Gay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Hematology, AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>High dose Melphalan</keyword>
  <keyword>Mobilization</keyword>
  <keyword>CD34</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

